Commercial Metrics
Summary of commercial performance metrics for due diligence. Detailed underlying data available on request.
Headline (2025)
Invoiced 2025
€848K
+145% YoY
Recognised revenue
€604K
+49% YoY
Top customers retention
92%
0% pharma churn
Active markets
7
ES, PT, PL, BR, US, UK, DE
Revenue trajectory
€22K
2020
€139K
2021
€197K
2022
€359K
2023
€405K
2024
€604K
2025
€1.3M
2026P
Recognised revenue. Cumulative 2020-2025: €1,727K invoiced (€2,045K signed).
The gap between invoiced contracts and recognised revenue (~€318K) reflects multi-year contracts that will be recognised in future periods.
Sales cycle (typical)
Pharma & CRO
9-12 mo
ACV €50K-€150K / project
0% churn · By new trial
Hospital / Public health
6-9 mo
ACV €20K-€60K / year
Annual recurring
Insurance
6-12 mo
ACV €40K-€150K / year
Annual recurring
Customer cohort stability
Johnson & Johnson
4-year relationship · Multiple expansion deals
Boehringer Ingelheim
3-year relationship
Ribera Salud / Hospital Torrejón
Long-term flagship customer
Sanitas / BUPA
Multi-year · Lux Med (BUPA Poland) added Q3 2025
Recent momentum (last 12 months)
Q1 2025
ANVISA Brazil certification obtained
Q3 2025
Lux Med (BUPA Poland) deal closed: entry to Polish market and BUPA Europe network
Q4 2025
€499K invoiced (59% of full-year total: significant Q4 acceleration)
Q1 2026
ICON (top-5 CRO globally) contract signed
Q1 2026
7th peer-reviewed paper published (AGPPGA, JMIR Dermatology)
Pipeline (CRM snapshot)
- Active opportunities: ~43
- Weighted pipeline value tracked in CRM
- Conversion rate (last 12 months): tracked in CRM
- Live CRM data available upon request
Customer concentration
Customer concentration is actively managed. Detailed concentration analysis (top 1, top 3, top 5 customer share) available upon request from CFO.